Tumor Regressions Observed During Combination Treatment with a Bi-Steric mTORC1-Selective Inhibitor and a KRAS G12C-Selective Inhibitor in Preclinical Lung Cancer Model that is Resistant to KRAS G12 C ...

An assessment of disease features and immune response in breast cancer patients that did not recur after receiving HER2 peptide, AE37 vaccine in a randomized phase II trial. This is an ASCO Meeting ...

Littdd Medicines Ltd. has described mTOR complex 1 (mTORC1) and/or mTOR complex 2 (mTORC2) inhibitors reported to be useful for the treatment of cancer, idiopathic pulmonary fibrosis, transplant ...

SILVER SPRING, Md., Dec. 16, 2025 /PRNewswire/ -- The TSC Alliance Endowment Fund, a supporting organization of the TSC Alliance, has invested in Aeovian Pharmaceuticals as part of their Series B ...

Aliad Biopharma Co. Ltd. has presented compounds acting as autophagy inducer, mTOR complex 1 (mTORC1) and mTORC2 inhibitors reported to be useful for the treatment of autism spectrum disorders, ...

First results from a phase I trial of AZD8055, a dual mTORC1 and mTORC2 inhibitor. Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and ...

Mammalian target of rapamycin (mTOR) inhibitors could be associated with acute nephrotoxicity, according to French researchers. The team describes 4 cancer patients who developed severe acute kidney ...

MINNEAPOLIS, July 24, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that the ...